{"transactions":[{"id":728549,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-23T21:21:15.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":9.51,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001777517-26-000002","document":"form4-06232026_090610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000177751726000002/form4-06232026_090610.xml","form_type":"4"}},{"id":976196,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-09T10:17:44.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-312122","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312122/ownership.xml","form_type":"4"}},{"id":976195,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:17:44.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9398,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"Company RSUs\") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312122","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312122/ownership.xml","form_type":"4"}},{"id":976194,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:17:44.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1200000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\") and Logos Opportunities Fund IV LP (\"LOF IV\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC (\"GP IV\") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312122","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312122/ownership.xml","form_type":"4"}},{"id":976193,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T10:17:44.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":93000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NN Invest Sub, Inc (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025 (such date and time, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the \"Closing Consideration\") and (ii) one contractual contingent value right (a \"CVR\") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-312122","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525312122/ownership.xml","form_type":"4"}},{"id":1020319,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":false,"shares":23832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":19.97,"expiration_date":"2029-11-07","underlying":"Common Stock","underlying_shares":23832},"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020318,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":25.2,"expiration_date":"2030-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020317,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":26.32,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020316,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020315,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are vested and currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020314,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":true,"shares":23832,"price":19.97,"value":475925.04,"ownership":{"direct":true},"balance_after":93000,"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020313,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":true,"shares":13000,"price":25.2,"value":327600.0,"ownership":{"direct":true},"balance_after":69168,"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020312,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":true,"shares":13000,"price":26.32,"value":342160.0,"ownership":{"direct":true},"balance_after":56168,"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020311,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":8.13,"value":121950.0,"ownership":{"direct":true},"balance_after":43168,"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1020310,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-10T19:48:05.000Z","date":"2025-10-08","kind":"exercise","planned":false,"acquired":true,"shares":26000,"price":23.02,"value":598520.0,"ownership":{"direct":true},"balance_after":28168,"source":{"system":"sec-edgar","filing":"0001193125-25-237295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312525237295/ownership.xml","form_type":"4"}},{"id":1110977,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:00:21.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":24150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":24150,"derivative":{"exercise_price":4.08,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":24150},"source":{"system":"sec-edgar","filing":"0001415889-25-017235","document":"form4-06132025_050617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588925017235/form4-06132025_050617.xml","form_type":"4"}},{"id":1121423,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T16:05:18.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":9398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest in full on the earlier of (i) June 3, 2026, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":11566,"source":{"system":"sec-edgar","filing":"0000950170-25-082306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025082306/ownership.xml","form_type":"4"}},{"id":1189875,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-27T19:42:13.000Z","date":"2025-03-27","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":43.554,"value":2177700.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\") and Logos Opportunities Fund IV LP (\"LOF IV\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC (\"GP IV\") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1200000,"source":{"system":"sec-edgar","filing":"0000950170-25-046271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025046271/ownership.xml","form_type":"4"}},{"id":1189874,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-27T19:42:13.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":58691,"price":43.012,"value":2524417.292,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\") and Logos Opportunities Fund IV LP (\"LOF IV\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC (\"GP IV\") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1150000,"source":{"system":"sec-edgar","filing":"0000950170-25-046271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025046271/ownership.xml","form_type":"4"}},{"id":1189873,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-27T19:42:13.000Z","date":"2025-03-25","kind":"purchase","planned":false,"acquired":true,"shares":91309,"price":44.747,"value":4085803.823,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\") and Logos Opportunities Fund IV LP (\"LOF IV\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC (\"GP IV\") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1091309,"source":{"system":"sec-edgar","filing":"0000950170-25-046271","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025046271/ownership.xml","form_type":"4"}},{"id":1278813,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T19:54:28.000Z","date":"2025-01-30","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":48,"value":9600000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\") and Logos Opportunities Fund IV LP (\"LOF IV\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC (\"GP IV\") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0000950170-25-016559","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017025016559/ownership.xml","form_type":"4"}},{"id":1326117,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T23:52:04.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":700761,"price":6.75,"value":4730136.75,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The Form 4 filed on December 17, 2024, inadvertently reported the number of shares held by Logos Fund IV after the transaction as 1,408,875. As reported in this amended Form 4, the number of shares held by Logos Fund IV after the transaction is 700,761. The Form 4 also mistakenly reported the purchase of shares by Logos Fund IV as a disposition. The transaction was an acquisition.  The transaction date was December 13, 2024."},{"field":"kind","element":"transactionCoding","label":"F3","text":"These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Opportunities Fund IV LP (\"Logos Fund IV\"). Logos Opportunities IV GP LLC (\"GP IV\") is the general partner of Logos Fund IV and the reporting person is a managing member of GP IV. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":700761,"source":{"system":"sec-edgar","filing":"0000935836-24-000764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583624000764/ownership.xml","form_type":"4/A","original_submission_date":"2024-12-17"}},{"id":1326116,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T23:52:04.000Z","date":"2024-12-13","kind":"sale","planned":false,"acquired":false,"shares":700761,"price":6.75,"value":4730136.75,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"The Form 4 filed on December 17, 2024 identified the transaction date as December 17, 2024.  The transaction date was December 13, 2024."},{"field":"kind","element":"transactionCoding","label":"F3","text":"These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Opportunities Fund I LP (\"Logos Fund I\"). Logos Opportunities GP, LLC (\"Logos Opportunities GP\") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000935836-24-000764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583624000764/ownership.xml","form_type":"4/A","original_submission_date":"2024-12-17"}},{"id":1327858,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T00:52:19.000Z","date":"2024-12-17","kind":"purchase","planned":false,"acquired":false,"shares":700761,"price":6.75,"value":4730136.75,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Opportunities Fund IV LP (\"Logos Fund IV\"). Logos Opportunities IV GP LLC (\"GP IV\")  is the general partner of Logos Fund IV and the reporting person is a managing member of GP IV. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1408875,"source":{"system":"sec-edgar","filing":"0000935836-24-000763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583624000763/ownership.xml","form_type":"4"}},{"id":1327857,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T00:52:19.000Z","date":"2024-12-17","kind":"sale","planned":false,"acquired":false,"shares":700761,"price":6.75,"value":4730136.75,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These securities were sold by Logos Fund I to Logos Fund IV. Logos Fund I and Logos Fund IV are under the common control of the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Opportunities Fund I LP (\"Logos Fund I\"). Logos Opportunities GP, LLC (\"Logos Opportunities GP\") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000935836-24-000763","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583624000763/ownership.xml","form_type":"4"}},{"id":1350518,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:48:49.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":475000,"price":14.85,"value":7053750.0,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Opportunities Fund II LP (\"Logos Fund II\"). Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":708114,"source":{"system":"sec-edgar","filing":"0000935836-24-000744","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583624000744/ownership.xml","form_type":"4/A","original_submission_date":"2024-06-06"}},{"id":1350517,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:48:49.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":700000,"price":14.85,"value":10395000.0,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Opportunities Fund I LP (\"Logos Fund I\"). Logos Opportunities GP, LLC (\"Logos Opportunities GP\") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":700761,"source":{"system":"sec-edgar","filing":"0000935836-24-000744","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583624000744/ownership.xml","form_type":"4/A","original_submission_date":"2024-06-06"}},{"id":1474411,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T21:00:25.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":23000,"derivative":{"exercise_price":12.36,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001415889-24-017448","document":"form4-06182024_050620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588924017448/form4-06182024_050620.xml","form_type":"4"}},{"id":1483552,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T17:29:55.000Z","date":"2024-06-08","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the earlier of (i) June 7, 2025, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board."}],"balance_after":26000,"derivative":{"exercise_price":23.02,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-072077","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017024072077/ownership.xml","form_type":"4"}},{"id":1488007,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T21:01:17.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":475000,"price":14.85,"value":7053750.0,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Opportunities Fund II LP (\"Logos Fund II\").  Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP.  The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":708114,"source":{"system":"sec-edgar","filing":"0000935836-24-000425","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583624000425/ownership.xml","form_type":"4"}},{"id":1488006,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T21:01:17.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":700000,"price":14.85,"value":10395000.0,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Opportunities Fund I LP (\"Logos Fund I\").  Logos Opportunities GP, LLC (\"Logos Opportunities GP\") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP.  The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":700761,"source":{"system":"sec-edgar","filing":"0000935836-24-000425","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583624000425/ownership.xml","form_type":"4"}},{"id":1706592,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-18T23:30:25.000Z","date":"2023-12-05","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":13.085,"value":654250.0,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1800000,"source":{"system":"sec-edgar","filing":"0000935836-23-000733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583623000733/ownership.xml","form_type":"4"}},{"id":1706591,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-18T23:30:25.000Z","date":"2023-12-05","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":14.9496,"value":747480.0,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1750000,"source":{"system":"sec-edgar","filing":"0000935836-23-000733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583623000733/ownership.xml","form_type":"4"}},{"id":1706590,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-18T23:30:25.000Z","date":"2023-12-05","kind":"purchase","planned":false,"acquired":true,"shares":31870,"price":14.7333,"value":469550.271,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1700000,"source":{"system":"sec-edgar","filing":"0000935836-23-000733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583623000733/ownership.xml","form_type":"4"}},{"id":1706589,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-18T23:30:25.000Z","date":"2023-09-12","kind":"purchase","planned":false,"acquired":true,"shares":508130,"price":9.84,"value":4999999.2,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1668130,"source":{"system":"sec-edgar","filing":"0000935836-23-000733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000093583623000733/ownership.xml","form_type":"4"}},{"id":1716366,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-11T21:06:30.000Z","date":"2023-12-08","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":19.854,"value":992700.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":800000,"source":{"system":"sec-edgar","filing":"0000950170-23-069509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023069509/ownership.xml","form_type":"4"}},{"id":1716365,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-11T21:06:30.000Z","date":"2023-12-08","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":19.8048,"value":990240.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":750000,"source":{"system":"sec-edgar","filing":"0000950170-23-069509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023069509/ownership.xml","form_type":"4"}},{"id":1721820,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T08:37:03.000Z","date":"2023-12-01","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":16.9946,"value":849730.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0000950170-23-067951","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023067951/ownership.xml","form_type":"4"}},{"id":1721819,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-05T08:37:03.000Z","date":"2023-11-30","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":16.8967,"value":844835.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":650000,"source":{"system":"sec-edgar","filing":"0000950170-23-067951","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023067951/ownership.xml","form_type":"4"}},{"id":1810900,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-10T16:46:42.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":42.059,"value":1051475.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $41.8634 to $42.3525, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":600000,"source":{"system":"sec-edgar","filing":"0000950170-23-041440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023041440/ownership.xml","form_type":"4"}},{"id":1819261,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-01T19:52:10.000Z","date":"2023-08-01","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":43.261,"value":1081525.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":575000,"source":{"system":"sec-edgar","filing":"0000950170-23-036694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023036694/ownership.xml","form_type":"4"}},{"id":1819260,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-01T19:52:10.000Z","date":"2023-07-28","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":42.6903,"value":1280709.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":550000,"source":{"system":"sec-edgar","filing":"0000950170-23-036694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023036694/ownership.xml","form_type":"4"}},{"id":1843494,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-27T17:48:41.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 23, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":50.83,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-23-030214","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023030214/ownership.xml","form_type":"4"}},{"id":1847421,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T21:00:25.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":7.84,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-23-010103","document":"form4-06212023_050607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588923010103/form4-06212023_050607.xml","form_type":"4"}},{"id":1854411,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T21:26:16.000Z","date":"2023-05-19","kind":"purchase","planned":false,"acquired":true,"shares":120000,"price":42,"value":5040000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":520000,"source":{"system":"sec-edgar","filing":"0000899243-23-015665","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924323015665/doc4a.xml","form_type":"4/A","original_submission_date":"2023-05-23"}},{"id":1854410,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-15T21:26:16.000Z","date":"2022-09-19","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":26,"value":10400000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This Form 4 amendment is being filed solely to correct the original Form 4 filed on May 23, 2023, which inadvertently included the incorrect transaction date of September 19, 2023, due to a clerical error. This amendment corrects the date of the transaction to September 19, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0000899243-23-015665","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924323015665/doc4a.xml","form_type":"4/A","original_submission_date":"2023-05-23"}},{"id":1881161,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-23T21:55:17.000Z","date":"2023-05-19","kind":"purchase","planned":false,"acquired":true,"shares":120000,"price":42,"value":5040000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":520000,"source":{"system":"sec-edgar","filing":"0000950170-23-023738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023023738/ownership.xml","form_type":"4"}},{"id":1881160,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-23T21:55:17.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":26,"value":10400000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0000950170-23-023738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000095017023023738/ownership.xml","form_type":"4"}},{"id":2220835,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T21:10:17.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is \"June 17, 2022\" and the correct exercise price is \"$3.61\" as shown herein."},{"field":"date","element":"transactionDate","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is \"June 17, 2022\" and the correct exercise price is \"$3.61\" as shown herein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":3.61,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-22-006961","document":"form4a-06272022_020606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588922006961/form4a-06272022_020606.xml","form_type":"4/A","original_submission_date":"2022-06-17"}},{"id":2226476,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T23:25:38.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":3.43,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-22-006782","document":"form4-06172022_040626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588922006782/form4-06172022_040626.xml","form_type":"4"}},{"id":2244913,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:06:06.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":15000,"derivative":{"exercise_price":8.13,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-020937","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000089924322020937/doc4.xml","form_type":"4"}},{"id":2668644,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-06-15T23:03:39.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":12004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders."}],"balance_after":12004,"derivative":{"exercise_price":59.66,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":12004},"source":{"system":"sec-edgar","filing":"0001209191-21-040738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121040738/doc4.xml","form_type":"4"}},{"id":2673217,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-10T22:38:13.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":27.66,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001415889-21-002926","document":"form4-06102021_030659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000141588921002926/form4-06102021_030659.xml","form_type":"4"}},{"id":2683493,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T17:55:36.000Z","date":"2021-06-01","kind":"gift","acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":25.2,"expiration_date":"2030-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-21-076496","document":"tm2118278-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921076496/tm2118278-2_4seq1.xml","form_type":"4"}},{"id":2683492,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T17:55:36.000Z","date":"2021-06-01","kind":"gift","acquired":false,"shares":23832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019."}],"balance_after":0,"derivative":{"exercise_price":19.97,"expiration_date":"2029-11-07","underlying":"Common Stock","underlying_shares":23832},"source":{"system":"sec-edgar","filing":"0001104659-21-076496","document":"tm2118278-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921076496/tm2118278-2_4seq1.xml","form_type":"4"}},{"id":2683491,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T17:55:36.000Z","date":"2021-06-01","kind":"gift","acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":0,"derivative":{"exercise_price":26.32,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-21-076496","document":"tm2118278-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921076496/tm2118278-2_4seq1.xml","form_type":"4"}},{"id":2683490,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T17:55:36.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":13000,"derivative":{"exercise_price":26.32,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-21-076496","document":"tm2118278-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465921076496/tm2118278-2_4seq1.xml","form_type":"4"}},{"id":2944633,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-16T00:07:07.000Z","date":"2020-12-14","kind":"purchase","acquired":true,"shares":20000,"price":76,"value":1520000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held of record by Logos Global Master Fund, L.P. (LGMF LP). As a managing member of Logos GP LLC, the general partner of LGMF LP, the reporting person   shares voting and dispositive power with respect to the shares held of record by LGMF LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":995000,"source":{"system":"sec-edgar","filing":"0000899243-20-033928","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320033928/doc4.xml","form_type":"4"}},{"id":2969382,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-11-23T21:35:58.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":1183114,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Logos Opportunities Fund II, L.P. (\"Logos Fund II\"). Logos Opportunities GP is the general partner of Logos Fund II and the Reporting Person is a managing member of Logos Opportunities GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1183114},"source":{"system":"sec-edgar","filing":"0001209191-20-059979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059979/doc4.xml","form_type":"4"}},{"id":2969381,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-11-23T21:35:58.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":1400761,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Opportunities Fund I L.P. (\"Logos Fund I\"). Logos Opportunities GP, LLC (\"Logos Opportunities GP\") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos Opportunities GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1400761},"source":{"system":"sec-edgar","filing":"0001209191-20-059979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059979/doc4.xml","form_type":"4"}},{"id":2969380,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-23T21:35:58.000Z","date":"2020-11-23","kind":"purchase","acquired":true,"shares":1160000,"price":19,"value":22040000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by Logos Global Master Fund LP (\"Logos Master Fund\"). Logos GP LLC (\"Logos GP\") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1160000,"source":{"system":"sec-edgar","filing":"0001209191-20-059979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059979/doc4.xml","form_type":"4"}},{"id":2969379,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-23T21:35:58.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":1183114,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Logos Opportunities Fund II, L.P. (\"Logos Fund II\"). Logos Opportunities GP is the general partner of Logos Fund II and the Reporting Person is a managing member of Logos Opportunities GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1183114,"source":{"system":"sec-edgar","filing":"0001209191-20-059979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059979/doc4.xml","form_type":"4"}},{"id":2969378,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-23T21:35:58.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":1400761,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Opportunities Fund I L.P. (\"Logos Fund I\"). Logos Opportunities GP, LLC (\"Logos Opportunities GP\") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos Opportunities GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1400761,"source":{"system":"sec-edgar","filing":"0001209191-20-059979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059979/doc4.xml","form_type":"4"}},{"id":2970757,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-11-20T23:43:26.000Z","date":"2020-06-01","kind":"purchase","acquired":true,"shares":339578,"price":4.7117,"value":1599989.6626,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Opportunities Fund I L.P. (\"Logos Fund I\"). Logos Opportunities GP, LLC (\"Logos GP\") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1400761,"derivative":{"underlying":"Common Stock","underlying_shares":339578},"source":{"system":"sec-edgar","filing":"0001209191-20-059760","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059760/doc4a.xml","form_type":"4/A","original_submission_date":"2020-11-19"}},{"id":2972615,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-20T00:01:19.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":21520,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001209191-20-059528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059528/doc4.xml","form_type":"4"}},{"id":2972614,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-20T00:01:19.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":21520,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001209191-20-059528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059528/doc4.xml","form_type":"4"}},{"id":2972613,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-20T00:01:19.000Z","date":"2020-11-18","kind":"grant","acquired":true,"shares":21520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21520,"derivative":{"exercise_price":19,"expiration_date":"2030-11-17","underlying":"Common Stock","underlying_shares":21520},"source":{"system":"sec-edgar","filing":"0001209191-20-059528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059528/doc4.xml","form_type":"4"}},{"id":2972612,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-11-20T00:01:19.000Z","date":"2020-09-30","kind":"purchase","acquired":true,"shares":1183114,"price":11.0623,"value":13087962.0022,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by Logos Opportunities Fund II, L.P. (\"Logos Fund II\"). Logos GP is the general partner of Logos Fund II and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":1183114,"derivative":{"underlying":"Common Stock","underlying_shares":1183114},"source":{"system":"sec-edgar","filing":"0001209191-20-059528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059528/doc4.xml","form_type":"4"}},{"id":2972611,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-11-20T00:01:19.000Z","date":"2020-06-01","kind":"purchase","acquired":true,"shares":339578,"price":4.7117,"value":1599989.6626,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Logos Opportunities Fund I L.P. (\"Logos Fund I\"). Logos Opportunies GP, LLC (\"Logos GP\") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."}],"balance_after":339578,"derivative":{"underlying":"Common Stock","underlying_shares":339578},"source":{"system":"sec-edgar","filing":"0001209191-20-059528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000120919120059528/doc4.xml","form_type":"4"}},{"id":3078892,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T00:04:53.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":2105901,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Logos Opportunities Fund I, L.P. (LOF I LP). As a managing member of Logos Opportunities GP, LLC, the general partner of LOF I LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LOF I LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2105901},"source":{"system":"sec-edgar","filing":"0000899243-20-019913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019913/doc4.xml","form_type":"4"}},{"id":3078891,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T00:04:53.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":975000,"price":19,"value":18525000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by Logos Global Master Fund, L.P. (LGMF LP). As a managing member of Logos GP LLC, the general partner of LGMF LP, the reporting person   shares voting and dispositive power with respect to the shares held of record by LGMF LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":975000,"source":{"system":"sec-edgar","filing":"0000899243-20-019913","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019913/doc4.xml","form_type":"4"}},{"id":3078890,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T00:04:53.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":2105901,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 56,080 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Logos Opportunities Fund I, L.P. (LOF I LP). As a managing member of Logos Opportunities GP, LLC, the general partner of LOF I LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LOF I LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2161981,"source":{"system":"sec-edgar","filing":"0000899243-20-019913","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019913/doc4.xml","form_type":"4"}},{"id":3080677,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-17T23:10:02.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":24009,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 36 equal monthly installments beginning on August 16, 2020."}],"balance_after":24009,"derivative":{"exercise_price":19,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":24009},"source":{"system":"sec-edgar","filing":"0000899243-20-019581","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019581/doc4.xml","form_type":"4"}},{"id":3127261,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T18:53:35.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":13000,"derivative":{"exercise_price":25.2,"expiration_date":"2030-05-31","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001104659-20-069072","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465920069072/a4.xml","form_type":"4"}},{"id":3189356,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-01T18:52:26.000Z","date":"2019-11-08","kind":"exercise","acquired":false,"shares":2168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019."}],"balance_after":23832,"derivative":{"exercise_price":19.97,"expiration_date":"2029-11-07","underlying":"Common Stock","underlying_shares":2168},"source":{"system":"sec-edgar","filing":"0001104659-20-042006","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465920042006/a4.xml","form_type":"4"}},{"id":3189355,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-01T18:52:26.000Z","date":"2020-03-30","kind":"exercise","acquired":true,"shares":2168,"price":19.97,"value":43294.96,"ownership":{"direct":true},"balance_after":2168,"source":{"system":"sec-edgar","filing":"0001104659-20-042006","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465920042006/a4.xml","form_type":"4"}},{"id":3374715,"issuer":{"id":71984,"kind":"organization","name":"Akero Therapeutics, Inc.","symbol":"AKRO"},"owners":[{"id":35885,"kind":"person","name":"Graham G. Walmsley","position":1,"cik":"0001777517","reported_name":"Graham G. Walmsley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-12T19:02:55.000Z","date":"2019-11-08","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019."}],"balance_after":26000,"derivative":{"exercise_price":19.97,"expiration_date":"2029-11-07","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001104659-19-062783","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744659/000110465919062783/a4.xml","form_type":"4"}}]}